



DEMO S.A.
PHARMACEUTICAL INDUSTRY



PRODUCT PIPELINE LIST

2020 - 2021

ACTIVE INGREDIENT	PHARMACEUTICAL FORM	STRENGTH	REFERENCE PRODUCT	THERAPEUTIC CLASS	DOSSIER AVAILABILITY
Cefoxitin	Powder for Solution for Injection	1g, 2g	MEFOXIN [Merck]	Anti-infective	Q3-2020
Furosemide	Solution for Injection	10mg/ml x 2ml/4ml/5ml/25ml	LASIX [Sanofi Aventis]	Diuretic	Q4-2020
Colistimethate sodium	Lyophilized Powder for Solution for Infusion	1MIU, 2MIU	COLOMYCIN [Forest laboratories]	Anti-infective	Q4-2020
	Powder for Nebulizer solution	1MIU, 2MIU			
Sugammadex	Solution for Injection	200mg/2ml, 500mg/5ml	BRIDION [MSD]	Reversal of rocuronium, neuromuscular blockade	Q4-2020
Acyclovir	Lyophilized Powder for Solution for Injection	500mg	ZOVIRAX [GSK]	Anti-infective	Q4-2020
Gadoterate Meglumine	Solution for Injection	27,9% 10ml, 15ml, 20ml	DOTAREM [Guerbet]	Xray gadolinium contrast medium	Q1-2021
Peritoneal dialysis solution	Peritoneal dialysis solution	6 presentations in 5L bags	Peritoneal Dialysis Solution with Dextrose [Baxter]	Peritoneal dialysis	Q2-2021
Amikacin	Solution for Injection	250mg/2ml, 500mg/2ml, 1000mg/4ml	BRIKLIN [BMS]	Anti-infective	Q2-2021
Clindamycin	Solution for Injection	300mg/2ml, 600mg/4ml, 900mg/6ml	DALACIN [Pfizer]	Anti-infective	Q2-2021
Vit B1, B2, B3, B6, C, Glucose	Concentrate for Solution for Infusion	Many ingredients in pairs of 5ml glass amps	Pabrinex [Kyowa Kirin]	Vitamims	Q3-2021
Dimetindene	Solution for Injection	4mg/4ml	FENISTIL [GSK]	Anti-histamine	Q3-2021
Metamizole	Solution for Injection	500mg/ml x 2ml and 5ml	NOVALGIN [Sanofi Aventis]	Anti-inflammatory, analgesic	Q3-2021
Trace elements	Concentrate for Solution for Infusion	As per ADDAVEN formula	ADDAVEN [Fresenius]	Supplement in intravenous nutrition	Q3-2021
Ibuprofen	Solution for Infusion	400mg/100ml, 600mg/100ml	NUROFEN [Reckitt Benckiser]	Anti-inflammatory, analgesic	Q4-2021
Tigecycline	Lyophilized Powder for injection	50mg	TYGACIL [Wyeth]	Anti-infective	Q4-2021

* None of the products will be supplied to countries in which this could be in conflict with existing patents; final responsibility lies exclusively with the buyer.